ClinicalTrials.gg
CompletedNCT03006874Updated Sep 12, 2017

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

A Phase 3 interventional study of CJ-12420 100mg QD and Esomeprazole 40mg in Erosive Esophagitis, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-09-12.

Sponsored by HK inno.N Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
302
Allocation
Randomized
Ages
20 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies in Esophagitis with a site in Korea, Republic of — none open to participants now, none under way, none of them phase 3. Esophagitis · Korea, Republic of.

Enrollment
5th of 12
302 · median 290
Started
2016
the only one that year
Phase 3
9 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
4 of 12
HK inno.N Corporation

Among the 12 studies in Esophagitis with a site in Korea, Republic of, this one is the 5th largest by enrollment, is the only one that started in 2016, is one of 9 in phase 3, and was the 4th registered.

Esophagitis

123 studies on the registry are indexed under Esophagitis; 15 are open to participants now.

Browse Esophagitis studies →

Open to participants now

None of the 12 studies in Esophagitis with a site in Korea, Republic of is open now. The open studies under Esophagitis, anywhere →

Who these studies take

Of the 10 Esophagitis studies recruiting now, 6 (60%) set no upper age limit and 4 (40%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 20 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Esophagitis with a site in Korea, Republic of as a file.
02

Study summary

The purpose of this study is to confirm the efficacy of CJ-12420, Once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.

Read the detailed description

This is a double blind, randomized, active controlled, phase 3 study. Subjects will be randomly assigned to one of the three treatment groups (CJ-12420 50mg, CJ-12420 100mg, esomeprazole 40mg).

All subjects will be asked to take three tablets at the same time each day throughout the study, and also all subjects will be asked to record daytime and nighttime symptom in a subject diary on a daily basis.

03

Conditions studied

  • Erosive Esophagitis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged between 20 and 75 years
  2. Endoscopically confirmed erosive esophagitis as defined by LA Classification Grading System (A-D) within 14 days prior to randomization
  3. Subjects who had experienced heartburn and regurgitation within 7 days before visit 1
  4. Subjects who is able to understand and follow the instructions and is willing to participate throughout the entire study
  5. Subjects who voluntarily signed written form
  6. Subjects who agreed to use medically acceptable during the period of study

Exclusion criteria

Exclusion Criteria:

  1. Subjects who cannot undergo EGD
  2. Subjects who have esophageal stenosis, ulcer stenosis, gastroesophageal varices, Barrett's esophagus, active gastric ulcer, gastrointestinal bleeding or malignant tumor confirmed by EGD
  3. Subjects who have warning symptoms of malignant gastrointestinal tract such as odynophagia, severe dysphagia, bleeding, weight loss, anemia, or bloody stool
  4. Subjects with eosinophilic esophagitis
  5. Subjects diagnosed with primary esophageal motility disorder, IBS, IBD, etc. or with suspected IBS in the last 3 months
  6. Subjects who have a history of gastric acid suppression surgery or upper gastrointestinal, esophageal surgery
  7. Subjects who have AIDS or Hepatitis
  8. Subjects who take antipsychotic drugs, antidepressant drug, antianxiety drug
  9. Subjects who take gastric acid suppression like PPI within 2 weeks to EGD
  10. Subjects who take medications related to reflux esophagitis more than 2 times within 1 weeks to EGD
  11. Requirement of persistent daily use of drugs that may cause an ulcer such as nonsteroidal anti-inflammatory drugs(NSAIDs) or aspirin during the course of the study
  12. Pregnant or lactating women
  13. Subjects with the following laboratory abnormalities
  14. Subjects with the following clinically significant abnormalities
  15. Sollinger-Ellison syndrome patients
  16. Subjects with a history of malignant tumor
  17. Subjects with a history of clinically significant hepatic, renal, cardiovascular, respiratory, endocrine and CNS system disorder
  18. Subjects with a history of to the active ingredient or of the study drug, etc
  19. Scheduled surgery requiring hospitalization or requirement of surgical treatment during study participation
  20. Subjects who participated in the other clinical trial within 4 weeks prior to randomization
  21. Subjects who are judged unsuitable to participate in the study in the opinion of the investigator
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
302 participants (actual)

Study arms

  • Experimental
    CJ-12420 50mg QD

    CJ-12420 50mg tablet, once daily, oral administration for up to 8 weeks.

    Drug: CJ-12420 50mg QD

  • Experimental
    CJ-12420 100mg QD

    CJ-12420 100mg tablet, once daily, oral administration for up to 8 weeks.

    Drug: CJ-12420 100mg QD

  • Active comparator
    Esomeprazole 40mg

    Esomeprazole 40mg, tablet. once daily, oral administration for up to 8 weeks.

    Drug: Esomeprazole 40mg

Interventions

  • CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.

    Also known as: Tegoprazan Tab.

  • Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.

    Also known as: Nexium Tab.

  • CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.

    Also known as: Tegoprazan Tab.

06

What researchers measure

Primary outcomes

  1. Cumulative healing rate of erosive esophagitis at 8-week

    Time frame: 8 week

Secondary outcomes

  1. Healing rate of erosive esophagitis at 4-week

    Time frame: 4-week

  2. Symptom assessment by subject diary

    Time frame: 4-week or 8-week

  3. Symptom assessment by questionnaire

    Time frame: 4-week or 8-week

07

Study locations

1 site
  • Samsung Medical Center
    Seoul, 135-710, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2016 to primary completion in Mar 2017, 10 months.

Of 18 phase 3 interventional studies under Esophagitis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 34. This study's 10 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 14, 2016
First posted
Dec 30, 2016
StartActual
May 2, 2016
Primary completionActual
Mar 24, 2017
CompletionActual
Mar 24, 2017
Last update
Sep 12, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03006874
Responsible party
Sponsor
First posted
Dec 30, 2016
Start date
May 2, 2016
Primary completion
Mar 24, 2017
Completion
Mar 24, 2017
Last update
Sep 12, 2017

Study contacts

Poong Ryul Lee, Ph.D
principal investigator · Samsung Medical Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion